APLS Jan 2026 80.000 call
| Previous close | 6.23 |
| Open | 6.43 |
| Bid | 2.55 |
| Ask | 4.40 |
| Strike | 80.00 |
| Expiry date | 2026-01-16 |
| Day's range | 6.20 - 6.43 |
| Contract range | N/A |
| Volume | |
| Open interest | 125 |
ZacksApellis (APLS) Posts Upbeat One-Year Kidney Diseases Study Data
Apellis (APLS) reports positive one-year data from the mid-stage study evaluating systemic pegcetacoplan to treat two rare and debilitating kidney diseases.
GlobeNewswirePositive One-Year Data from Phase 2 Study of Pegcetacoplan in Post-Transplant Recurrence of C3G and IC-MPGN Presented as Late-Breaker at ERA Congress
Rapid reduction in disease activity seen at 12 weeks was sustained at one year 55% of patients showed zero C3c staining intensity, indicating that C3c deposits were clearedHighlighted as late-breaking oral presentation at the European Renal Association (ERA) Congress WALTHAM, Mass. and STOCKHOLM, Sweden, May 24, 2024 (GLOBE NEWSWIRE) -- Apellis Pharmaceuticals, Inc. (Nasdaq: APLS) and Sobi® (STO:SOBI) today announced positive one-year results from the Phase 2 NOBLE study investigating systemic p
- GlobeNewswire
Apellis Pharmaceuticals Refinances Existing Debt with Up to $475 Million Non-Dilutive Credit Facility from Sixth Street
Apellis received $375 million in funding at close, with ability to access an additional $100 millionMajority of initial proceeds used to buy out existing SFJ Pharmaceuticals development liability Significantly improves liquidity profile by eliminating $366 million in SFJ payments through 2027 WALTHAM, Mass., May 14, 2024 (GLOBE NEWSWIRE) -- Apellis Pharmaceuticals, Inc. (Nasdaq: APLS), today announced that it has entered into a non-dilutive, senior secured credit facility with Sixth Street, a le
